Antimicrobial agents and chemotherapy

(Antimicrob Agents Chemother) ISSNs: , 1098-6596

References in Antimicrobial agents and chemotherapy:

Search this table:

Title	Authors	Year
Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure.	Chou S, Marousek G, Bowlin TL	2011
Antiviral effects of aphidicolin, a new antibiotic produced by Cephalosporium aphidicola.	Bucknall RA, Moores H, Simms R, Hesp B	1973
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.	Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC	1997
Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.	Diallo K, Oliveira M, Moisi DD, Brenner BG, Wainberg MA, Götte M	2002
The Mechanism of Interaction of Human Mitochondrial DNA Polymerase γ with the Novel Nucleoside Reverse Transcriptase Inhibitor 4' -Ethynyl-2-Fluoro-2' -Deoxyadenosine Indicates a Low Potential for Host Toxicity.	Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS	2011
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.	Naito T, Izumi K, Kodama EN, Sakagami Y, Kajiwara K, Nishikawa H, Watanabe K, Sarafianos SG, Oishi S, Fujii N, Matsuoka M	2009
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.	Boyer PL, Gao HQ, Hughes SH	1998
Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.	Boyer PL, Hughes SH	1995
Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.	Boyer PL, Ding J, Arnold E, Hughes SH	1994
Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.	Hanes JW, Johnson KA	2008
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.	Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, Schinazi RF, Furman PA, Anderson KS	2004
Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.	Wainberg MA, Brenner BG, Turner D	2005
Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.	Hizi A, Tal R, Shaharabany M, Currens MJ, Boyd MR, Hughes SH, McMahon JB	1993
Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptases.	Schinazi RF, Eriksson BF, Hughes SH	1989
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine.	Furman PA, Jeffrey J, Kiefer LL, Feng JY, Anderson KS, Borroto-Esoda K, Hill E, Copeland WC, Chu CK, Sommadossi JP, Liberman I, Schinazi RF, Painter GR	2001
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.	Richman DD	1993
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.	Smith RA, Klarmann GJ, Stray KM, von Schwedler UK, Schinazi RF, Preston BD, North TW	1999
Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.	Buckheit RW, Snow MJ, Fliakas-Boltz V, Kinjerski TL, Russell JD, Pallansch LA, Brouwer WG, Yang SS	1997
Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse Transcriptase.	Kirby KA, Marchand B, Ong YT, Ndongwe TP, Hachiya A, Michailidis E, Leslie MD, Sietsema DV, Fetterly TL, Dorst CA, Singh K, Wang Z, Parniak MA, Sarafianos SG	2012
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.	Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, D'Aquila RT	1994
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.	Tisdale M, Alnadaf T, Cousens D	1997
Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.	Diallo K, Götte M, Wainberg MA	2003
Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.	Lacey SF, Larder BA	1994
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.	Cherrington JM, Mulato AS, Fuller MD, Chen MS	1996
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.	Gosselin G, Schinazi RF, Sommadossi JP, Mathé C, Bergogne MC, Aubertin AM, Kirn A, Imbach JL	1994
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.	Diallo K, Brenner BG, Oliveira M, Moisi DD, Detorio M, Götte M, Wainberg MA	2003
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.	Zhang Z, Walker M, Xu W, Shim JH, Girardet JL, Hamatake RK, Hong Z	2006
Herpes simplex virus mutants resistant to arabinosyladenine in the presence of deoxycoformycin.	Fleming HE, Coen DM	1984
Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication.	Kleim JP, Bender R, Billhardt UM, Meichsner C, Riess G, Rösner M, Winkler I, Paessens A	1993
L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.	Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carroll SS	1995
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.	Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G, Abremski K	2000
Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines.	Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM, Mellors JW	1994
Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.	Buckheit RW, Kinjerski TL, Fliakas-Boltz V, Russell JD, Stup TL, Pallansch LA, Brouwer WG, Dao DC, Harrison WA, Schultz RJ	1995
Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.	Maass G, Immendoerfer U, Koenig B, Leser U, Mueller B, Goody R, Pfaff E	1993
S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.	Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H, Hatanaka M, Hinuma Y	1998
In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.	Yoshimura K, Feldman R, Kodama EN, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H	1999
Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.	Fitzgibbon JE, Howell RM, Haberzettl CA, Sperber SJ, Gocke DJ, Dubin DT	1992
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.	Witvrouw M, Arranz ME, Pannecouque C, Declercq R, Jonckheere H, Schmit JC, Vandamme AM, Diaz JA, Ingate ST, Desmyter J, Esnouf R, Van Meervelt L, Vega S, Balzarini J, De Clercq E	1998
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication.	Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Rösner M, Rübsamen-Waigmann H, Kaiser R, Wichers M, Schneweis KE	1995
Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.	Balzarini J, Brouwer WG, Dao DC, Osika EM, De Clercq E	1996
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.	Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW	2000
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.	Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA	1994
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.	Richard N, Salomon H, Rando R, Mansour T, Bowlin TL, Wainberg MA	2000
Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors.	Byrnes VW, Sardana VV, Schleif WA, Condra JH, Waterbury JA, Wolfgang JA, Long WJ, Schneider CL, Schlabach AJ, Wolanski BS	1993
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.	Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS, Mitsuya H	1997
Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases.	Brown JA, Pack LR, Fowler JD, Suo Z	2011
Mechanism of resistance to GS-9148 conferred by the Q151L mutation in HIV-1 reverse transcriptase.	Scarth BJ, White KL, Chen JM, Lansdon EB, Swaminathan S, Miller MD, Götte M	2011
Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H.	Chung S, Wendeler M, Rausch JW, Beilhartz GL, Gotte M, O'Keefe BR, Bermingham A, Beutler JA, Liu S, Zhuang X, Le Grice SF	2010
GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.	Wolfgang GH, Shibata R, Wang J, Ray AS, Wu S, Doerrfler E, Reiser H, Lee WA, Birkus G, Christensen ND, Andrei G, Snoeck R	2009
Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.	Mukaide M, Tanaka Y, Shin-I T, Yuen MF, Kurbanov F, Yokosuka O, Sata M, Karino Y, Yamada G, Sakaguchi K, Orito E, Inoue M, Baqai S, Lai CL, Mizokami M	2010
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.	Crespan E, Locatelli GA, Cancio R, Hübscher U, Spadari S, Maga G	2005
Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.	Maga G, Hübscher U, Pregnolato M, Ubiali D, Gosselin G, Spadari S	2001
Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.	Yang G, Paintsil E, Dutschman GE, Grill SP, Wang CJ, Wang J, Tanaka H, Hamasaki T, Baba M, Cheng YC	2009
Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.	Paolucci S, Baldanti F, Maga G, Cancio R, Zazzi M, Zavattoni M, Chiesa A, Spadari S, Gerna G	2004
Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.	Locatelli GA, Campiani G, Cancio R, Morelli E, Ramunno A, Gemma S, Hübscher U, Spadari S, Maga G	2004
Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes.	Maga G, Ubiali D, Salvetti R, Pregnolato M, Spadari S	2000
Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphate.	Yang G, Wang J, Cheng Y, Dutschman GE, Tanaka H, Baba M, Cheng YC	2008
Inhibition of murine leukemia virus with poly-2'-O-(2,4-dinitrophenyl)poly[A].	Ashun MA, Hu Y, Kang I, Li CC, Wang JH	1996
Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.	Turner D, Brenner BG, Moisi DD, Detorio M, Cesaire R, Kurimura T, Mori H, Essex M, Maayan S, Wainberg MA	2004
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.	Doualla-Bell F, Avalos A, Brenner BG, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA	2006
SARS-CoV Replication Inhibitor that Interferes with the Nucleic acid Unwinding of the Viral Helicase.	Adedeji AO, Singh K, Calcaterra NE, Dediego ML, Enjuanes L, Weiss S, Sarafianos SG	2012
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.	Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA	2010
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.	Petrella M, Oliveira M, Moisi DD, Detorio M, Brenner BG, Wainberg MA	2004
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.	Loemba H, Brenner BG, Parniak MA, Ma'ayan S, Spira B, Moisi DD, Oliveira M, Detorio M, Wainberg MA	2002
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.	Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL, Rando RF	1999
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.	Borkow G, Arion D, Wainberg MA, Parniak MA	1999
The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.	Kew Y, Salomon H, Olsen LR, Wainberg MA, Prasad VR	1996
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.	Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM	1993
Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.	Xu H, Quan Y, Brenner BG, Bar-Magen T, Oliveira M, Schader SM, Wainberg MA	2009
Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.	Andrei G, Sienaert R, McGuigan C, De Clercq E, Balzarini J, Snoeck R	2005
Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives.	Stevens M, Pannecouque C, De Clercq E, Balzarini J	2003
Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.	Kramer VG, Schader SM, Oliveira M, Colby-Germinario SP, Donahue DA, Singhroy DN, Tressler R, Sloan RD, Wainberg MA	2012
Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs.	Thormar H, Balzarini J, Holy A, Jindrich J, Rosenberg I, Debyser Z, Desmyter J, De Clercq E	1993
Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.	Cherry E, Slater M, Salomon H, Rud E, Wainberg MA	1997
Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.	Shi M, Wang X, De Clercq E, Takao S, Baba M	2007
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.	Ntemgwa ML, Wainberg MA, Oliveira M, Moisi DD, Lalonde RG, Micheli V, Brenner BG	2007
Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations.	Oliveira M, Moisi DD, Spira B, Cox S, Brenner BG, Wainberg MA	2009
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.	Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi DD, Toni TD, Tremblay CL	2011
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.	Gu Z, Salomon H, Cherrington JM, Mulato AS, Chen MS, Yarchoan R, Foli A, Sogocio KM, Wainberg MA	1995
A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors.	Motakis D, Parniak MA	2002
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.	Vanpouille C, Lisco A, Introini A, Grivel JC, Munawwar A, Merbah M, Schinazi RF, Derudas M, McGuigan C, Balzarini J, Margolis L	2012
Antiadenovirus activities of several classes of nucleoside and nucleotide analogues.	Naesens L, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holy A, Balzarini J, De Clercq E	2005
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.	Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi PJ, Vanham G, Janssen P	2004
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.	Witvrouw M, Balzarini J, Pannecouque C, Jhaumeer-Laulloo S, Esté JA, Schols D, Cherepanov P, Schmit JC, Debyser Z, Vandamme AM, Desmyter J, Ramadas SR, De Clercq E	1997
Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.	Balzarini J, Baba M, De Clercq E	1995
Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.	Quan Y, Brenner BG, Oliveira M, Wainberg MA	2003
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.	de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA, Rando RF	1999
Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.	Mercure L, Brenner BJ, Phaneuf D, Tsoukas C, Wainberg MA	1994
Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.	Abdurahman S, Végvári A, Youssefi M, Levi M, Höglund S, Andersson E, Horal P, Svennerholm B, Balzarini J, Vahlne A	2008
Novel human immunodeficiency virus (HIV) inhibitors that have a dual mode of anti-HIV action.	Stevens M, Pannecouque C, De Clercq E, Balzarini J	2003
[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1.	Balzarini J, Pérez-Pérez MJ, San-Félix A, Velazquez S, Camarasa MJ, De Clercq E	1992
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.	Ptak RG, Gallay PA, Jochmans D, Halestrap AP, Ruegg UT, Pallansch LA, Bobardt MD, De Béthune MP, Neyts J, De Clercq E, Dumont JM, Scalfaro P, Besseghir K, Wenger RM, Rosenwirth B	2008
Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir.	Suzutani T, Ishioka K, De Clercq E, Ishibashi K, Kaneko H, Kira T, Hashimoto K, Ogasawara M, Ohtani K, Wakamiya N, Saijo M	2003
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.	Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR, De Clercq E, Witvrouw M, Neamati N, Debyser Z	2002
The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.	Neyts J, Andrei G, De Clercq E	1998
The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.	Neyts J, Andrei G, De Clercq E	1998
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.	Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MA, De Clercq E	1994
Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.	Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT, De Clercq E	1994
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.	Van Vaerenbergh K, Van Laethem K, Albert J, Boucher CA, Clotet B, Floridia M, Gerstoft J, Hejdeman B, Nielsen C, Pannecouque C, Perrin L, Pirillo MF, Ruiz L, Schmit JC, Schneider F, Schoolmeester A, Schuurman R, Stellbrink HJ, Stuyver L, Van Lunzen J, Van Remoortel B, Van Wijngaerden E, Vella S, Witvrouw M, Yerly S, De Clercq E, Destmyer J, Vandamme AM	2000
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.	Neyts J, De Clercq E	1999
The Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and their Interactions with the M184I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine.	Xu HT, Colby-Germinario SP, Asahchop EL, Oliveira M, McCallum M, Schader SM, Han Y, Quan Y, Sarafianos SG, Wainberg MA	2013
Basis for the Early and Preferential Selection of the E138K Substitution in HIV-1 Reverse Transcriptase with Etravirine.	McCallum M, Oliveira M, Ibanescu RI, Kramer VG, Moisi DD, Asahchop EL, Brenner BG, Harrigan R, Xu H, Wainberg MA	2013
Effects of 4' - and 2-Substitutions on the Bioactivity of 4' -Ethynyl-2-Fluoro-2' -Deoxyadenosine.	Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG	2013

Showing 1 to 103 of 103 entries